# Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

> **NCT07553390** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells
- **DRUG:** Trastuzumab deruxtecan (T-DXd)
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT07553390
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2036-03-30
- **Final completion:** 2038-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553390, "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07553390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*